Hussain Joins Northwestern; Douillard Named ESMO CMO

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MAHA HUSSAIN will join the Robert H. Lurie Comprehensive Cancer Center of Northwestern University as associate director for clinical sciences research, effective Sept. 1.

Hussain will also serve as co-director of the Lurie Cancer Center’s Genitourinary Oncology Program, along with Edward Schaeffer, chair of the Department of Urology at Northwestern University Feinberg School of Medicine. Hussain is currently Cis-Maisel Professor of Oncology, and professor of medicine and urology at the University of Michigan.

She has served in many scientific and leadership roles at the University of Michigan including associate director for clinical research and co-leader of the Prostate Cancer/GU Oncology Program at the UMComprehensive Cancer Center, as well as associate chief for clinical research in the Division of Hematology/Oncology.

Hussain’s research focuses on the development of therapeutics for prostate and bladder cancer. At Northwestern, Hussain will oversee the clinical sciences research programs and working groups, and foster interdisciplinary and inter-programmatic collaborations.

“We are thrilled to welcome Maha to the Lurie Cancer Center,” said Director Leonidas Platanias. “She is one of the world’s leading researchers in the field of prostate cancer and her presence will strengthen our clinical research efforts immensely.”

Hussain’s national scientific leadership roles include serving as co-chair of the Prostate Cancer Subcommittee/Genitourinary Cancer Committee of SWOG; as a member and chair of the integration panel of the U.S. Army Medical Research and Materiel Command Prostate Cancer Research Program; and as a member and chair of the FDA Oncology Drug Advisory Committee.

Hussain has held leadership roles within the American Society of Clinical Oncology and was recently elected to ASCO’s board of directors. She currently serves on ASCO’s Clinical Practice Guidelines Committee, as a member of the National Comprehensive Cancer Network International Committee and the Advanced Prostate Cancer Panel of the American Urological Association.

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login